Press Releases - 2023-08-10

Date	Title	Company
10-Aug-2023	Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results	Businesswire
10-Aug-2023	Envoy Report Reveals 80% of Executives Set Their Return-to-Office Policies Without Critical Workplace Data	Businesswire
10-Aug-2023	Dr. Reddy's Laboratories Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S.	Businesswire
10-Aug-2023	Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress	Businesswire
10-Aug-2023	KBI Biopharma, Inc. Continues to Strengthen Leadership and Expertise With Key Executive Appointments	Businesswire
10-Aug-2023	Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments	Vaccitech plc
10-Aug-2023	atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)	atai Life Sciences
10-Aug-2023	KBI Biopharma, Inc. Continues to Strengthen Leadership and Expertise With Key Executive Appointments	KBI Biopharma, Inc.
10-Aug-2023	Phastar Appoints Graham Clark as New Chief Executive Officer	Phastar
10-Aug-2023	CNX Therapeutics to expand hospital-injectable portfolio and international presence through the acquisition of four cancer support therapies from Clinigen	CNX Therapeutics
10-Aug-2023	Elixia Health Enters Phase I Clinical Trials Market	Newswire
10-Aug-2023	NHS report shows diabetes drugs prescribed increased by 16 million since 2015/16	NHS Business Services Authority’s (NHSBSA)
10-Aug-2023	Leaping into the future with quantum-inspired fiber sensor technology	QUANTIFISENS
10-Aug-2023	4SC provides Q2 2023 and H1 2023 update	4SC
10-Aug-2023	Syncona Limited First Quarter Update	Syncona Limited
10-Aug-2023	Bloomsbury Genetic Therapies Receives Orphan Drug Designation from the U.S. FDA for BGT-OTCD for the Treatment of Ornithine Transcarbamylase Deficiency (OTCD)	Bloomsbury Genetic Therapies Limited
10-Aug-2023	STORM Therapeutics to present the discovery of lead clinical candidate STC-15 at the American Chemical Society Fall 2023 Conference	STORM Therapeutics
10-Aug-2023	MED3000 approved for Commercialisation in Saudi Arabia under the brand name Eroxon®	Futura Medical plc
10-Aug-2023	Innovative Trials to help advance children’s cancer care through new UK charity partnership	Innovative Trials
10-Aug-2023	Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia	Businesswire